Fate Therapeutics Soars as Much as 45.8% After Giving Investors What They Wanted

Shares of Fate Therapeutics (NASDAQ: FATE) jumped as much as 45.8% today after the company gave investors what they've long craved: data.

The company is developing novel immunotherapies based on natural killer (NK) cells, whereas most drug candidates in the industry's pipeline rely on T cells. NK cells have numerous inherent advantages but have delivered mixed clinical results to date for competitors, so investors approached the pharma company with caution. That all changed today.

Fate Therapeutics is making six presentations at the Annual Meeting of the American Society of Hematology (ASH). The first handful was made over the weekend and show that the company's was to cellular medicines has promise.

Continue reading

Source Fool.com